These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 12497980)
1. Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment. Pépin J; Mpia B; Iloasebe M Trans R Soc Trop Med Hyg; 2002; 96(4):421-6. PubMed ID: 12497980 [TBL] [Abstract][Full Text] [Related]
2. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Pépin J; Milord F; Khonde A; Niyonsenga T; Loko L; Mpia B Trans R Soc Trop Med Hyg; 1994; 88(4):447-52. PubMed ID: 7570842 [TBL] [Abstract][Full Text] [Related]
3. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Pépin J; Mpia B Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288 [TBL] [Abstract][Full Text] [Related]
4. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Pépin J; Milord F; Khonde AN; Niyonsenga T; Loko L; Mpia B; De Wals P Trans R Soc Trop Med Hyg; 1995; 89(1):92-7. PubMed ID: 7747321 [TBL] [Abstract][Full Text] [Related]
5. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358 [TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357 [TBL] [Abstract][Full Text] [Related]
7. Epidemiological evidence for immunity following Trypanosoma brucei gambiense sleeping sickness. Khonde N; Pépin J; Niyonsenga T; Milord F; De Wals P Trans R Soc Trop Med Hyg; 1995; 89(6):607-11. PubMed ID: 8594669 [TBL] [Abstract][Full Text] [Related]
8. [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo]. Eozenou P; Jannin J; Ngampo S; Carme B; Tell GP; Schechter PJ Med Trop (Mars); 1989; 49(2):149-54. PubMed ID: 2507863 [TBL] [Abstract][Full Text] [Related]
9. [Importance of familial contamination in Trypanosoma brucei gambiense trypanosomiasis]. Henry MC Bull Soc Pathol Exot Filiales; 1981; 74(1):65-71. PubMed ID: 7296731 [TBL] [Abstract][Full Text] [Related]
10. Population genetics of Trypanosoma brucei gambiense in sleeping sickness patients with treatment failures in the focus of Mbuji-Mayi, Democratic Republic of the Congo. Pyana PP; Sere M; Kaboré J; De Meeûs T; MacLeod A; Bucheton B; Van Reet N; Büscher P; Belem AMG; Jamonneau V Infect Genet Evol; 2015 Mar; 30():128-133. PubMed ID: 25535944 [TBL] [Abstract][Full Text] [Related]
11. Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Pépin J; Khonde N Trans R Soc Trop Med Hyg; 1996; 90(2):183-6. PubMed ID: 8761585 [TBL] [Abstract][Full Text] [Related]
12. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness. Mumba Ngoyi D; Lejon V; Pyana P; Boelaert M; Ilunga M; Menten J; Mulunda JP; Van Nieuwenhove S; Muyembe Tamfum JJ; Büscher P J Infect Dis; 2010 Feb; 201(3):453-63. PubMed ID: 20047500 [TBL] [Abstract][Full Text] [Related]
13. Familial aggregation of Trypanosoma brucei gambiense trypanosomiasis in a very high incidence community in Zaire. Khonde N; Pépin J; Niyonsenga T; De Wals P Trans R Soc Trop Med Hyg; 1997; 91(5):521-4. PubMed ID: 9463655 [TBL] [Abstract][Full Text] [Related]
14. The impact of human immunodeficiency virus infection on the epidemiology and treatment of Trypanosoma brucei gambiense sleeping sickness in Nioki, Zaire. Pepin J; Ethier L; Kazadi C; Milord F; Ryder R Am J Trop Med Hyg; 1992 Aug; 47(2):133-40. PubMed ID: 1503182 [TBL] [Abstract][Full Text] [Related]
15. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Legros D; Evans S; Maiso F; Enyaru JC; Mbulamberi D Trans R Soc Trop Med Hyg; 1999; 93(4):439-42. PubMed ID: 10674099 [TBL] [Abstract][Full Text] [Related]
16. Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness. Pepin J; Milord F; Guern C; Mpia B; Ethier L; Mansinsa D Lancet; 1989 Jun; 1(8649):1246-50. PubMed ID: 2566790 [TBL] [Abstract][Full Text] [Related]
17. Card agglutination test for trypanosomiasis (CATT) end-dilution titer and cerebrospinal fluid cell count as predictors of human African Trypanosomiasis (Trypanosoma brucei gambiense) among serologically suspected individuals in southern Sudan. Chappuis F; Stivanello E; Adams K; Kidane S; Pittet A; Bovier PA Am J Trop Med Hyg; 2004 Sep; 71(3):313-7. PubMed ID: 15381812 [TBL] [Abstract][Full Text] [Related]
18. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: an open trial in central Zaire. Pépin J; Milord F; Meurice F; Ethier L; Loko L; Mpia B Trans R Soc Trop Med Hyg; 1992; 86(3):254-6. PubMed ID: 1412646 [TBL] [Abstract][Full Text] [Related]
19. Polysomnography as a diagnosis and post-treatment follow-up tool in human African trypanosomiasis: a case study in an infant. Mpandzou G; Cespuglio R; Ngampo S; Bandzouzi B; Bouteille B; Vincendeau P; Buguet A J Neurol Sci; 2011 Jun; 305(1-2):112-5. PubMed ID: 21470639 [TBL] [Abstract][Full Text] [Related]
20. The risk factors for relapse among patients with African trypanosomiasis in Daloa, Cote d'Ivoire. Cross P; Doua F; Jaffar S Trop Doct; 2006 Apr; 36(2):90-3. PubMed ID: 16611441 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]